Celularity Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Celularity Inc. (CELU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.16 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-04-30
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $3.50.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $3.39.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.16, a 56.39% decline from fiscal 2024.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $2.66, a 50.28% decline from fiscal 2023.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $5.35, a 1.47% decline from fiscal 2022.
- Celularity Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $5.43, a 31.48% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.16 10-K · filed 2026-04-30 | |||
| 2025-09-30 | $1.95 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | $1.89 10-Q · filed 2025-08-29 | |||
| 2025-03-31 | $0.00 10-Q · filed 2025-08-29 | |||
| 2024-12-31 | $2.66 10-K · filed 2026-04-30 | |||
| 2024-09-30 | $3.10 10-Q · filed 2025-11-14 | |||
| 2024-06-30 | $3.42 10-Q · filed 2025-08-29 | |||
| 2024-03-31 | $3.50 10-Q · filed 2025-08-29 | |||
| 2023-12-31 | $5.35 10-K · filed 2025-05-08 | |||
| 2023-09-30 | $0.39 10-Q · filed 2024-12-06 | |||
| 2023-06-30 | $0.54 10-Q · filed 2024-11-07 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-22 | |||
| 2022-12-31 | $5.43 10-K · filed 2024-07-30 | |||
| 2022-09-30 | $5.60 10-Q · filed 2024-01-03 | |||
| 2022-06-30 | $6.23 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | $3.39 10-Q · filed 2023-05-22 | |||
| 2021-12-31 | $4.13 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $4.13 10-Q · filed 2021-11-12 | |||
| 2020-12-31 | $2.24 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |